Tanis J Ferman1, Naoya Aoki2, Julia E Crook3, Melissa E Murray4, Neill R Graff-Radford5, Jay A van Gerpen5, Ryan J Uitti5, Zbigniew K Wszolek5, Jonathan Graff-Radford6, Otto Pedraza7, Kejal Kantarci8, Bradley F Boeve6, Dennis W Dickson4. 1. Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA. Electronic address: ferman.tanis@mayo.edu. 2. Department of Psychiatry, Yokohama City University Medical Center, Yokohama, Japan. 3. Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA. 4. Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. 5. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. 6. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 7. Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA. 8. Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Abstract
INTRODUCTION: We sought to assess the individual and combined contribution of limbic and neocortical α-synuclein, tau, and amyloid β (Aβ) to duration of illness in dementia with Lewy bodies (DLB). METHODS: Quantitative digital pathology of limbic and neocortical α-synuclein, tau, and Aβ was assessed in 49 patients with clinically probable DLB. Regression modeling examined the unique and shared contribution of each pathology to the variance of illness duration. RESULTS: Patients with diffuse Lewy body disease had more severe pathology of each type and a shorter duration of illness than individuals with transitional Lewy body disease. The three pathologies accounted for 25% of the total variance of duration of illness, with 19% accounted for by α-synuclein alone or in combination with tau and Aβ. When the diffuse Lewy body disease group was examined separately, α-synuclein deposition significantly exceeded that of tau and Aβ. In this model, 20% of 24% total variance in the model for duration of illness was accounted for independently by α-synuclein. DISCUSSION: In DLB, α-synuclein is an important predictor of disease duration, both independently and synergistically with tau and Aβ.
INTRODUCTION: We sought to assess the individual and combined contribution of limbic and neocortical α-synuclein, tau, and amyloid β (Aβ) to duration of illness in dementia with Lewy bodies (DLB). METHODS: Quantitative digital pathology of limbic and neocortical α-synuclein, tau, and Aβ was assessed in 49 patients with clinically probable DLB. Regression modeling examined the unique and shared contribution of each pathology to the variance of illness duration. RESULTS:Patients with diffuse Lewy body disease had more severe pathology of each type and a shorter duration of illness than individuals with transitional Lewy body disease. The three pathologies accounted for 25% of the total variance of duration of illness, with 19% accounted for by α-synuclein alone or in combination with tau and Aβ. When the diffuse Lewy body disease group was examined separately, α-synuclein deposition significantly exceeded that of tau and Aβ. In this model, 20% of 24% total variance in the model for duration of illness was accounted for independently by α-synuclein. DISCUSSION: In DLB, α-synuclein is an important predictor of disease duration, both independently and synergistically with tau and Aβ.
Authors: H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold Journal: Neurology Date: 2000-05-23 Impact factor: 9.910
Authors: Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack Journal: Neurobiol Aging Date: 2011-10-21 Impact factor: 4.673
Authors: Hiroshige Fujishiro; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Neill R Graff-Radford; Ryan J Uitti; Zbigniew K Wszolek; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson Journal: J Neuropathol Exp Neurol Date: 2008-07 Impact factor: 3.685
Authors: W Peelaerts; L Bousset; A Van der Perren; A Moskalyuk; R Pulizzi; M Giugliano; C Van den Haute; R Melki; V Baekelandt Journal: Nature Date: 2015-06-10 Impact factor: 49.962
Authors: Olga Pletnikova; Neva West; Michael K Lee; Gay L Rudow; Richard L Skolasky; Ted M Dawson; Laura Marsh; Juan C Troncoso Journal: Neurobiol Aging Date: 2004-12-28 Impact factor: 4.673
Authors: Erica Howard; David J Irwin; Katya Rascovsky; Naomi Nevler; Sanjana Shellikeri; Thomas F Tropea; Meredith Spindler; Andres Deik; Alice Chen-Plotkin; Andrew Siderowf; Nabila Dahodwala; Daniel Weintraub; Leslie M Shaw; John Q Trojanowski; Sanjeev N Vaishnavi; David A Wolk; Dawn Mechanic-Hamilton; James F Morley; John E Duda; Murray Grossman; Katheryn A Q Cousins Journal: Neurology Date: 2021-02-16 Impact factor: 9.910
Authors: Daniel Ferreira; Scott A Przybelski; Timothy G Lesnick; Afina W Lemstra; Elisabet Londos; Frederic Blanc; Zuzana Nedelska; Christopher G Schwarz; Jonathan Graff-Radford; Matthew L Senjem; Julie A Fields; David S Knopman; Rodolfo Savica; Tanis J Ferman; Neill R Graff-Radford; Val J Lowe; Clifford R Jack; Ronald C Petersen; Brit Mollenhauer; Sara Garcia-Ptacek; Carla Abdelnour; Jakub Hort; Laura Bonanni; Ketil Oppedal; Milica G Kramberger; Bradley F Boeve; Dag Aarsland; Eric Westman; Kejal Kantarci Journal: Neurology Date: 2020-09-28 Impact factor: 9.910
Authors: Tanis J Ferman; Naoya Aoki; Bradley F Boeve; Jeremiah A Aakre; Kejal Kantarci; Jonathan Graff-Radford; Joseph E Parisi; Jay A Van Gerpen; Neill R Graff-Radford; Ryan J Uitti; Otto Pedraza; Melissa E Murray; Zbigniew K Wszolek; R Ross Reichard; Julie A Fields; Owen A Ross; David S Knopman; Ronald C Petersen; Dennis W Dickson Journal: Neurology Date: 2020-06-19 Impact factor: 9.910
Authors: Jodie B Nichols; Michael Malek-Ahmadi; Pierre N Tariot; Geidy E Serrano; Lucia I Sue; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2021-02-22 Impact factor: 3.685